Federal award (DEFINITIVE CONTRACT, fiscal year 2023)
Recipient: VAXART BIOSCIENCES INC
Awarding agency: Department of Health and Human Services / Office of Assistant Secretary for Preparedness and Response
Funding agency: Department of Health and Human Services / Office of Assistant Secretary for Preparedness and Response
Period of performance: 2024-01-12 to 2024-07-12
Current total value of award: $9271191
Description: CLINICAL TRIAL PLANNING ACTIVITIES FOR A PHASE 2B CLINICAL TRIAL THAT COMPARES VAXART'S XBB VACCINE CANDIDATE TO AN MRNA COMPARATOR TO EVALUATE EFFICACY FOR SYMPTOMATIC AND ASYMPTOMATIC DISEASE, SYSTEMIC AND MUCOSAL IMMUNE INDUCTION, AND ADVERSE